Waters’ Q2 Revenue Swells 13 Percent, But Ongoing ‘Tough’ Rx Climate Dampens Outlook | GenomeWeb
Coming off a challenging first quarter in its pharmaceutical business, Waters officials cast a skeptical eye at that business for the foreseeable future as it released its second-quarter earnings this week.
 
As normally the first of the large proteomics tool manufacturers to report its quarterly financial results, Waters has often provided a preview of the influences at play in the field and what to possibly expect from its competitors. As such, upcoming rival reports on pharma spending may remain gloomy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.